What are Medical Device De Novo Requests?

Updated October 26, 2024

A De Novo request is a regulatory tool for classifying and approving novel medical devices. For manufacturers and innovators, understanding this pathway is a prerequisite for market entry. This article explains what De Novo requests are, their role in the FDA clearance process, and the submission mechanics. We will also cover potential outcomes, common challenges, and the future of De Novo requests in FDA regulation.

Why this matters

The De Novo pathway allows novel technologies to reach patients when no existing classification fits. Without it, many new devices with low to moderate risk and no predicate would face immense barriers to market entry. The mechanism ensures these devices receive proper scrutiny for safety and effectiveness. They avoid being automatically designated as high-risk Class III devices, which require costly Premarket Approval (PMA) applications. The FDA's "Cybersecurity in Medical Devices" Final Guidance, dated February 3, 2026, makes clear that cybersecurity is fundamental to device safety and effectiveness for all classifications, including those set by a De Novo. Any manufacturer seeking a De Novo classification must build cybersecurity into the earliest design stages. This means aligning with recognized standards like IEC 81001-5-1 for health IT safety, ISO 14971 for risk management, and AAMI TIR57 / ANSI/AAMI SW96:2023 for security risk management. Ignoring these requirements can cause long delays or rejection, which risks both market access and patient safety. De Novo requests act as a bridge, balancing innovation with strict regulatory oversight as medical device cybersecurity evolves.

Understanding the Basics of De Novo Request

Definition of De Novo Request

A De Novo request, formally called an Evaluation of Automatic Class III Designation, is a submission to the U.S. Food and Drug Administration (the FDA). Its purpose is to classify a medical device that has no legally marketed predicate. This pathway exists for novel devices that fall outside the existing classification framework.

A manufacturer can choose the De Novo process when its new device has no suitable predicate for a 510(k) comparison. The pathway allows the FDA to evaluate the device on its own merits, then determine the correct risk classification and set regulatory requirements.

History and Evolution of De Novo Request

The De Novo process was created under the FDA Modernization Act of 1997. Its goal was to improve the regulatory path for new medical devices, especially those with low to moderate risk. Over the years, the FDA has worked to streamline the process, speeding up the evaluation of novel devices to encourage innovation while protecting patient safety.

As technology advances and new device types appear, the De Novo pathway has become more central to the FDA's regulatory framework. It provides a mechanism for timely market access when a new device has no predicate for comparison. The process supports innovation and improved patient care by offering a clear route for evaluating and classifying these devices.

The Importance of De Novo Request in Medical Device Classification

Role of De Novo Request in FDA Clearance Process

The De Novo pathway is a key part of the FDA clearance process, creating the initial classification for new devices. It allows a manufacturer to get authorization from the FDA and establish a device classification. This classification becomes the foundation for all later regulatory work, including future premarket submissions, quality control, and postmarket surveillance.

The pathway offers a direct approach for devices that lack a predicate or do not fit existing categories. This flexibility is necessary as medical technology changes and traditional pathways fail to account for novel device features. By classifying these devices, the De Novo process creates clear regulations and helps speed market access for new technologies.

Impact on Medical Device Innovation

The De Novo pathway has had a major impact on medical device innovation. By offering a route for devices without a predicate, it encourages manufacturers to develop and introduce new technologies. This leads to advancements in patient care and treatment.

The De Novo pathway also increases competition and market diversity. It enables new companies to bring unique products to market, which prevents monopolies and creates a competitive environment that benefits providers and patients. This competition encourages continuous improvement in product development and patient outcomes.

The Process of Submitting a De Novo Request

Preparing for a De Novo Submission

A successful De Novo request demands careful preparation and deep knowledge of the FDA’s requirements. Manufacturers must research their device to identify its unique features, intended use, and potential risks. Key preparation steps include gathering clinical data, conducting all necessary testing, and proving compliance with relevant regulations.

You must also create a clear timeline for submission. This timeline should account for internal reviews and potential revisions based on FDA feedback. Working with regulatory consultants or other experts can provide valuable guidance during preparation and help ensure the submission package is complete and ready for review.

Components of a De Novo Request

A strong De Novo request must include several key components that demonstrate the device’s safety, effectiveness, and patient benefits. A submission typically includes a device description, intended use and indications for use, labeling, risk analysis, clinical data, bench testing results, and a summary of any adverse events. A complete and well-structured submission increases the likelihood of a positive outcome.

Pay close attention to formatting and organization. All required sections should be clearly labeled and easy to find. Detailed references and supporting documents strengthen the submission’s validity and help reviewers assess the device’s performance. The best way to improve the chances of approval is to demonstrate a deep understanding of the device and its impact on patient care.

Evaluating the Outcome of a De Novo Request

Possible Outcomes and Their Implications

After evaluating a De Novo request, the FDA can issue one of three outcomes. It can grant the request and establish a new device classification, refuse the request, or request additional information. The outcome directly affects the manufacturer and the device's market entry. A positive outcome can create opportunities for market access, reimbursement, and partnerships. A negative one may require more work or modifications to address regulatory concerns.

When the FDA grants a De Novo request, it has determined the device is low to moderate risk and can be marketed. This decision validates the manufacturer’s work and allows for commercialization. A manufacturer can use this success to distinguish its product in a competitive market, attract investors, and build credibility with providers and patients.

Understanding FDA’s Decision Criteria

The FDA evaluates De Novo requests based on specific criteria. These include the device’s intended use, technical characteristics, safety and effectiveness, patient risks and benefits, and the lack of a suitable predicate. Manufacturers must address these criteria completely, providing solid evidence and scientific reasoning to support their request. Understanding the FDA’s decision-making process helps manufacturers build a strong De Novo submission.

Consider engaging regulatory consultants or other experts with experience in the FDA review process. These professionals can offer useful insights, help identify potential pitfalls, and assist in developing a strategy to improve the odds of a favorable outcome. Proactively addressing the FDA's decision criteria and seeking expert guidance is the best way to increase the chance of success.

Challenges and Considerations in De Novo Request Process

See also: Breakthrough Device Designation and Cybersecurity, FDA Penetration Testing Requirements, and Letter to File vs New 510(k).

Working through the De Novo process presents challenges that demand careful thought and strategic planning. Beyond common submission pitfalls, you must anticipate regulatory hurdles and market issues that could affect clearance. Manufacturers must stay informed about the changing regulatory environment and be ready to adapt their submission strategy.

Understanding the competitive market is necessary to position a device effectively. Thorough market research and identifying unmet clinical needs can help a manufacturer tailor its De Novo request to emphasize the device's value and what makes it different from existing solutions.

Common Pitfalls in De Novo Submission

To avoid unnecessary delays or rejection, manufacturers must be aware of common pitfalls in the De Novo submission process. These challenges include providing inadequate data to support safety or effectiveness, unclear intended use and indications, failing to distinguish the device from any potential predicates, and submitting incomplete or poorly organized materials.

Strategies for Successful De Novo Request

Manufacturers can use several strategies to improve the odds of a successful De Novo request. Involve regulatory experts early in development. Conduct thorough testing and clinical studies. Engage with the FDA through pre-submission meetings. Address the FDA’s decision criteria clearly and concisely. Finally, provide strong evidence to support all safety and effectiveness claims.

Future of De Novo Request in FDA Regulation

Recent Changes and Their Impact

The FDA has recently made changes to streamline the De Novo process and improve its efficiency. The changes aim to reduce evaluation times, improve communication with manufacturers, and support the development of novel medical devices. Understanding and adapting to these changes is critical for any manufacturer using the De Novo pathway.

One major change is the Pre-Submission Program. This program allows manufacturers to engage with the FDA early in development to get feedback and guidance. By seeking input from the FDA before filing a De Novo request, manufacturers can address potential issues and ensure their submission meets all requirements. This proactive approach saves time and improves the chances of a successful approval.

Predicted Trends in De Novo Request Usage

The use of De Novo requests will likely continue to increase as medical device innovation accelerates. As technologies grow more complex and diverse, the De Novo pathway offers a flexible framework for introducing new devices and giving patients access to advanced healthcare. To remain competitive, manufacturers must stay informed about trends and developments in the De Novo process.

One key trend is the use of artificial intelligence (AI) in medical devices. AI-powered devices can change healthcare by improving diagnostic accuracy, personalizing treatments, and enhancing patient monitoring. As these AI devices enter the market, manufacturers must use the De Novo process to meet FDA regulations. Understanding how AI fits into the De Novo framework and addressing the unique challenges of these devices will be required for any manufacturer seeking approval.

De Novo, 510(k), and PMA compared

A De Novo has no predicate, so nothing absorbs a weak security file. It is judged on what you put in it.

Conclusion

The De Novo request is a core mechanism for classifying and approving novel medical devices that lack a predicate. To succeed, manufacturers and innovators must understand its fundamentals, its role in FDA clearance, and how to work through the submission process. By meeting the challenges, using effective strategies, and keeping up with regulatory changes, manufacturers can use the De Novo pathway to advance medical device innovation and improve patient care.

As the industry innovates and works through FDA regulations, cybersecurity cannot be an afterthought. Blue Goat Cyber is a Veteran-Owned business specializing in medical device cybersecurity. We help ensure your products meet all compliance standards, including HIPAA and FDA requirements. With expertise in penetration testing and securing medical devices, we can help prepare your product for its path to market. Contact us today for cybersecurity help to safeguard your devices against potential threats.

How Blue Goat approaches this

Blue Goat Cyber helps medical device manufacturers prepare strong De Novo submissions by focusing on verifiable cybersecurity evidence. The process begins with a deep analysis of the device's cybersecurity architecture and intended use environment. We help identify vulnerabilities, assess risks, and develop mitigation strategies that align with the FDA's expectations for novel devices. Our team of certified professionals, including CISSP and OSCP holders and ex-military red teamers, specializes in creating the documentation for cybersecurity controls and testing. We guide manufacturers through threat modeling, risk management, and control implementation, generating the materials needed for a successful De Novo classification. The goal is to streamline the regulatory process. If the FDA finds cybersecurity deficiencies in a submission we prepared, we resolve them at no additional cost. Learn more about our specialized support at: /services/fda-premarket-cybersecurity-services.

If you want one team to own the whole cybersecurity package, see our full-service FDA premarket cybersecurity submission support.

FAQ

What is a De Novo Request?

A De Novo Request is a pathway for the FDA to classify novel medical devices that have no legally marketed predicate device into Class I or Class II, based on their risk level. This process allows these devices to enter the market.

When should a manufacturer consider a De Novo Request?

Manufacturers should consider a De Novo Request when their medical device is novel and does not fit within an existing classification, meaning there is no predicate device for a 510(k) submission, or if a 510(k) has been deemed Not Substantially Equivalent (NSE).

How does the De Novo process impact medical device innovation?

The De Novo process supports medical device innovation by providing a clear regulatory pathway for novel devices. This encourages manufacturers to develop new technologies and ensures patients have access to advanced healthcare solutions.

What information is needed for a De Novo submission?

A De Novo submission requires a device description, intended use, indications for use, labeling, detailed risk analysis, clinical data, and bench testing results, all supporting the device's safety and effectiveness.

What are the possible outcomes of a De Novo Request?

The FDA can grant the request and establish a new device classification, refuse the request, or ask for additional information. A granted request opens opportunities for market access and further development.

Does the FDA premarket cybersecurity guidance apply to De Novo devices?

Yes, all medical devices, including those cleared through the De Novo pathway, must comply with the FDA's February 3, 2026 final guidance on premarket cybersecurity. Cybersecurity is a critical aspect of device safety and effectiveness.

Related: Medical Device Cybersecurity: A Complete Lifecycle Guide